Low-resource settings are disproportionately burdened by infectious diseases and antimicrobial resistance. Good quality clinical bacteriology through a well functioning reference laboratory network is necessary for effective resistance control, but low-resource settings face infrastructural, technical, and behavioural challenges in the implementation of clinical bacteriology. In this Personal View, we explore what constitutes successful implementation of clinical bacteriology in low-resource settings and describe a framework for implementation that is suitable for general referral hospitals in low-income and middle-income countries with a moderate infrastructure. Most microbiological techniques and equipment are not developed for the specific needs of such settings. Pending the arrival of a new generation diagnostics for these settings, we suggest focus on improving, adapting, and implementing conventional, culture-based techniques. Priorities in low-resource settings include harmonised, quality assured, and tropicalised equipment, consumables, and techniques, and rationalised bacterial identification and testing for antimicrobial resistance. Diagnostics should be integrated into clinical care and patient management; clinically relevant specimens must be appropriately selected and prioritised. Open-access training materials and information management tools should be developed. Also important is the need for onsite validation and field adoption of diagnostics in low-resource settings, with considerable shortening of the time between development and implementation of diagnostics. We argue that the implementation of clinical bacteriology in low-resource settings improves patient management, provides valuable surveillance for local antibiotic treatment guidelines and national policies, and supports containment of antimicrobial resistance and the prevention and control of hospital-acquired infections.
Introduction
Bacterial sepsis is a leading cause of mortality and critical illness worldwide. [1] [2] [3] Antimicrobial resistance is considered a major threat to global health and low-income and middle-income countries 4 are disproportionally burdened. 5, 6 Contributing factors include patients' vulnerability to invasive bacterial illness, uncontrolled use of antibiotics, and poor laboratory support for clinical diagnosis resulting in overuse of antibiotics. Further, practices to prevent health care-acquired infections are generally absent in low-resource settings. 5 Clinical bacteriology is the laboratory work-up needed for identification, quantification, and antibiotic susceptibility testing of bacteria found in clinical patient samples. Doing effective clinical bacteriology supports three of the five strategic objectives identified by WHO for containment of antimicrobial resistance: surveillance, appropriate use of antibiotics (antibiotic stewardship), and infection control in health-care settings. 7 These objectives were reaffirmed at the UN General Assembly's high-level meeting on antimicrobial resistance in September, 2016. 8 Clinical bacteriology contributes substantially to patients' diagnosis and guides antibiotic treatment. For severe sepsis, inappropriate antimicrobial therapy is a major contributor to mortality and sepsis guidelines emphasise the importance of culture-guided therapy. 9 For tropical low-resource settings, inappropriate therapy is particularly problematic because life-threatening bacterial infections, such as non-typhoidal Salmonella spp bloodstream infections, are often clinically indistinguishable from severe Plasmodium falciparum infection [10] [11] [12] [13] and are often misdiagnosed. 14, 15 Identification of bacterial pathogens and antimicrobial susceptibility testing allow optimisation, de-escalation, or discontinuation of antibiotic treatment, resulting in improved patient outcomes, reduced costs, and reduced selection of antimicrobial resistance. 16 Culture data from patient samples can be aggregated to identify common pathogens and determine their susceptibility patterns. Such local surveillance data will support validation of empirical guidelines for antibiotic treatment. 17 In addition, daily reviews of clinical bacteriology data are vital for the detection of hospital-associated or communityassociated outbreaks and to monitor emergence of resistance. 18, 19 Diagnostic laboratories in low-income and middleincome countries face challenges of infrastructure, equipment, logistics, quality-assurance, and human resources. 20 In the past decade, considerable efforts have been made to improve laboratory systems in low-resource settings. [21] [22] [23] Although diagnostics for tuberculosis, malaria, HIV, and Ebola virus have been successfully disseminated, 5, 24 clinical bacteriology covers a wide spectrum of pathogens and cannot be achieved by simple diagnostic and therapeutic algorithms or by a few rapid diagnostic tests or vertical control programmes. Furthermore, the design, development, and clinical validation of new diagnostics for clinical bacteriology can take 2-10 years. 25 The dissemination of diagnostics in lowresource settings comes with additional challenges, including procurement, distribution, and quality control issues. 26 In addition, manufacturers' production capacity and compliance with ISO standards (ISO 13485) are
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often inadequate in such settings. 27 Further, with the advances in mass spectrometry technologies and automated bacterial identification and antimicrobial susceptibility testing in high-resource settings, the gap between these systems and practices of clinical bacteriology in low-resource settings has widened. Pending the implementation of new technologies, conventional culture-based techniques are still the best option for the application of clinical bacteriology in these settings; they are well studied, robust, universally accepted, and most have regulatory certification. Moreover, culture-based techniques are still essential for antimicrobial susceptibility testing, even in the presence of molecular or biomarker tests.
A framework towards the implementation of clinical bacteriology in low-resource settings, including common obstacles and global priorities, is urgently needed. In this Personal View we aim to describe a framework for implementation that is suitable for general referral hospitals in low-resource settings with a moderate infrastructure (ie, a basic diagnostic laboratory operated by laboratory staff without expertise in microbiology). 28 Although focused on operational and technical requirements, this framework will inform clinicians and health-care policy makers. We briefly discuss laboratory services in low-resource settings, such as supranational initiatives involved in funding, accreditation, diagnostic regulations, and manufacturing. [20] [21] [22] [29] [30] [31] [32] Clinical bacteriology in low-resource settings: six building blocks Based on our collective expert opinion and review of the available literature, we propose that six essential building blocks have to be addressed for successful implementation of clinical bacteriology in low-resource settings.
Availability of equipment and consumables adapted for use in low-resource settings
Environmental conditions in low-resource settings affect electronic equipment and consumables, such as glassware and dehydrated culture media 33 (table 1, figure 1) . Availability of quality-assured diagnostics is further compromised by the absence of onsite production and inadequate supply chains, which are incompatible with the shelf life and cold storage requirements of many diagnostic kits. 41 In addition, there is little commercial interest in the development of new diagnostics adapted for use in low-resource settings because of low profit margins. 5 Equipment and consumables for diagnostics in low-resource settings need to be adapted so that they are resistant to harsh conditions, such as temperature, humidity, dust, sunlight, and transport. In addition to being robust, safe, and stable, equipment should consume little energy and be easy to maintain. Consumables (such as culture media or test reagents) need to have a long shelf life and generate little waste. Where possible, internal quality controls should be included in reagent kits. Quality assurance in manufacturing, client support, post-marketing service, and maintenance should be guaranteed.
A first step towards adaptation of diagnostics equipment for use in low-income settings is to draft clear profiles of target products and technical specifications by regulatory agencies, manufacturers, and stakeholders. Some manufacturers have already launched research initiatives for low-cost innovation that target fever-related diagnostics in low-resource settings. 86 Furthermore, manufacturers in growing economies (such as China, Vietnam, and Thailand) are producing a wide range of diagnostics hitherto unknown outside their domestic markets. Some diagnostics used in clinical bacteriology (such as reagents used for phenotypical tests and serotyping) have not been extensively validated for stability and shelf life, which might have been arbitrarily set, for example, at 25°C and 6 months. However, actual use (and some guidelines) suggests a reliable performance outside these specifications 87 and identical products from different manufacturers have different storage and shelf life requirements. Therefore, in line with current practice for pharmaceutical products, 88 extended product stability testing (including temperature and storage stability) should be done to confirm the true limits in low-resource settings.
Other short-term goals are tropicalised packaging (eg, vacuum-sealed packaging to protect against humidity), clear labelling, and adaptation of instructions to an appropriate language and educational level. 89, 90 Furthermore, production of quality-assured consumables (such as culture media and phenotypical test reagents) can be outsourced to a centralised facility as has been done in Cambodia. 91 Medium-term objectives include the development of low tech, low cost, and low maintenance equipment, such as electricity-free incubators, 92 battery-operated centrifuges, 93 and autocleaves powered by solar energy. [94] [95] [96] Alternatives for sheep blood, horse blood, and rabbit plasma should be explored; for example, goat, pig, and hair sheep (a breed of sheep adapted to tropical climates) blood are alternatives to sheep blood for homemade culture media, 97, 98 but lyophilised or synthetic media should also be considered. Likewise, agar (ie, solidifying substrate in culture media) is obtained from sea algae at a few harvesting sites; substrates such as cellulose produced by engineered bacteria 99 should be assessed as a commercial alternative.
Rationalised bacterial identification and antimicrobial susceptibility testing
Because of recent technological advances in identification techniques and continuous improvements to guidelines for antimicrobial susceptibility testing, state-of-the-art identification and testing in low-resource settings remains a major challenge (table 1) . 41 Although [34] [35] [36] [37] Basic requirements frequently not met: 5, 30 power, climate control and ventilation, dust reduction, water quality, light sources, biosafety requirements, and internet connectivity Diagnostics Increasing development of diagnostics 38, 39 Sales are not lucrative enough for adequate return on investment to create rapid diagnostic solutions 5 Quality assurance
Quality-assured production and supply by ISO 13485 certified manufacturers 40 Limited quality assurance of process and products; 41 diagnostics manufacturers are often not certified by ISO 13485 27 Consumables Procurement and supply chain of diagnostics short and reliable General absence of locally produced consumables; when locally produced, consumables are often substandard with poor quality assurance and irregular availability; 42 some reagents are subject to dangerous goods regulations when shipped by air; 43 long delivery delays in combination with short shelf life and need for cold chain (2-8°C or as low as -20°C) for critical products; high stress conditions (heat, humidity) and limited environmental stability 30 Logistics Storage, stock management, and distribution systems in place Stock management and inventory systems are not in place or inappropriate 30 
Standard operating procedures
Standards for standard operating procedures covered by ISO15189 or equivalent quality management system 34 The creation of and updating of standard operating procedures and other documents are a significant obstacle; 30 multiple language and cultural barriers to the understanding of such procedures 44 Reference materials
Reference materials are easily accessible Reference materials (such as culture type strains) are expensive, subject to strict shipment requirements 40 51, 52 Antimicrobial susceptibility testing of bacteria
Harmonised criteria by international guidelines (CLSI, EUCAST) integrated in automated antimicrobial susceptibility testing methods assuring correct and updated use of breakpoints and expert rules 53, 54 Guidelines are often temporary, not well disseminated, only available in English, and poorly followed; 41 expert rules are too complicated to be mastered by staff without expertise in microbiology Laboratory processes
Streamlined and automated trajectory with the help of Laboratory Information Management Systems contributes to shortening of preanalytical phase and post-analytical phase 55, 56 Piecemeal sampling, paper-based systems, with hardcopy results collected too late or not at all; 57 accuracy of results is seen as more important than speed and short turnaround time
Laboratory criteria
Clinically relevant criteria for sampling 58 No laboratory guidance for selection, sampling, and transport of specimens results in inadequate sampling (eg, fistula and wound swabs, long transport delays); sampling biased to patients who are severely ill, failed initial treatment, or can afford testing 45, 100 building local capacity to implement annual revisions of such guidelines is a major challenge.
The relevance of the need to identify all bacteria to the species level is debatable; 101 grouping genera and species according to their clinical relevance might be more useful. 47 We propose the adoption of a two-tier approach consisting of first-line identification to the group level with preliminary antimicrobial susceptibility testing, followed by a more advanced identification and testing at national reference laboratories. Practical guidelines for grouping bacteria according to clinical relevance, antimicrobial resistance profile, hospital epidemiology, and public health importance should be undertaken. Table 2 shows how Gram-negative enteric bacteria can be grouped according to clinical and infection control relevance. 48, 101, 117, 118 In most laboratories, the detail and level of identification of bacteria will be dependent also on the technical and economic feasibility of the identification system used.
The grouping of bacteria would encourage technologies for abbreviated identification through so-called spot tests, which are single substrate biochemical or enzymatic tests that can be read via colour, fluorescence, or turbidity. Spot tests, already available for key pathogens such as Escherichia coli, Staphylococcus aureus, and Pseudomonas aeruginosa, are reliable and can contribute to clinical decision making. 58, 119, 120 Valuable documents, such as the Clinical and Laboratory Standards Institute guidelines for the identification for bacteria and yeasts, 119 should be updated, extended to tropical bacteria (eg, Salmonella spp, Burkholderia pseudomallei), validated with geographically representative strains, and made open access.
Testing panels for antimicrobial susceptibility should be adapted to the requirements of low-resource settings (eg, harmonised with the country's essential drug list). Disk diffusion testing has advantages of cost, flexibility, simplicity, and reliability. However, simplified tests for minimal inhibitory concentration-such as lyophilised microbroth dilution methods-could be less prone to error and are sometimes required (eg, ceftriaxone for Streptococcus pneumoniae). Simple and affordable reading apparatus would be helpful for accurate interpretations, Infection control
Real-time alert function for infection control (community and hospitalbased outbreaks) 76 Infection control committees rarely work with laboratory data for outbreak investigation and management 5, 74 Surveillance All laboratories take part in surveillance of (re-)emerging pathogens and vaccine-preventable diseases 77 Public health surveillance is mostly confined to reference laboratories 
Communication between the laboratory and clinicians
The interface between clinicians and the diagnostic laboratory is poorly studied in low-resource settings. 60, 69, 121 Guided by their reliance on clinical algorithms and syndromic approaches, clinicians are reluctant to request laboratory tests (table 1); a tendency that is aggravated by their perception that tests are expensive, slow, and often irrelevant. 65 In some regions, patients fear blood sampling and invasive procedures ( figure 2) . 65, 66 Additionally, senior managers in hospitals are typically academic clinicians, which increases the gap in communication between decision makers, clinicians, and laboratory staff. Laboratory staff often feel underappreciated and have limited professional opportunites. 69, 121 In high-resource settings, clinical bacteriology is closely integrated with patient management and infection prevention and control. 59, 122 Such integration does not exist in low-resource settings, where trained clinical microbiologists are rare and the main focus of the laboratory work is on the analytical phase, with little professional collaboration and communication between laboratory staff and clinicians. 20, 60 Therefore, even when good quality diagnostic laboratories exist in low-resource settings, their impact is frequently compromised by underuse, inadequate specimen collection, or postanalytical issues (such as ineffective reporting of results). 5, 33, 65, 69 We advocate regular person-to-person interactions between clinicians and laboratory staff to address the communication gap and further highlight the importance of this interaction through pre-service and continuous training. 123, 124 The Strengthening Laboratory Management Toward Accreditation (SLMTA) programme provides useful strategies on how to improve communication between clinicians and laboratory staff. 78, 125 Likewise, the modules for specimen collection and test result reporting in the SLMTA toolkit could help to strengthen clinical bacteriology activities in low-resource settings.
Prioritisation of clinically relevant specimens
Although key to performance, 78 the minimal number of samples (critical volume) that should be processed to acquire expertise in clinical bacteriology is not defined. Clinical bacteriology relies on the competence and experience of laboratory staff; for example, the Gram stain, which provides crucial information during diagnosis of blood cultures, 126, 127 is notoriously prone to error in inexperienced hands. 128 Further, laboratories in low-resource settings tend to process few samples and often use inappropriately selected specimens ( Salmonella dysenteriae serotype 1 is frequently involved in epidemics 115 Detail and level of identification is dependent on technical and economic feasibility of the identification system used. We focused on isolates recovered from bloodstream pathogens. Multidrug resistance is defined as resistance to at least one agent in three or more antibiotic classes. 116 ESBL=extended spectrum beta-lactamase. *If technically feasible and affordable, separate identification of this species would be desirable. †WHO's priority pathogen list is a global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. 
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When resources are limited, we propose the prioritisation of key clinical specimens (table 3)-for example, blood cultures are highly relevant for patient management and for antimicrobial resistance surveillance. 18 By contrast, culture of cerebrospinal fluid, with its stringent culture requirements, might not have added clinical value (ie, after cell count and Gram stain testing) because standard treatment with third generation cephalosporins in the postneonatal period covers most bacterial pathogens. 133, 141, 142 Specimens from empyema, abscesses, and osteomyelitis, and surgical samples can guide clinical care, but procedures for these specimens are considerably more complex than laboratory work-up of blood culture samples or urine samples. 136 Clear sampling procedures and acceptance criteria need to be formalised, communicated, and implemented. 124 
Provision of accessible and affordable training and reference materials
Training materials dedicated to clinical bacteriology in low-resource settings are scarce, seldom updated, and sometimes expensive. Training (both theoretical and practical) and reference materials should be specific to the setting, open access, available in local languages, and be readable and comprehensible for non-expert users of various cultural backgrounds. 44 End-user feedback and validation is useful to refine and improve teaching materials. 44 Established guidance and toolkits should be linked to reference materials, including SLMTA toolkit modules, the Stepwise Laboratory Improvement Towards Accreditation checklist, 79 also offer guidance on how to assess laboratories and national laboratory systems.
Onsite training of clinicians, nurses, and laboratory staff will encourage the highest efficiency and retention. Experiences from the implementation of clinical medicine in low-resource settings highlight the value of onsite support through educational outreach and mentoring visits. 144 The role of bench-side coaching by experienced professionals cannot be underestimated as a way of teaching good clinical practice. 145 Remote learning with video is a valuable complement to bench-side exposure; 146 for example, the European Committee for Antimicrobial Susceptibility Testing has released instruction videos for disk diffusion. 147 Telemicrobiology, which is the transfer of images of cultures and microscopy, allows for real-time analysis, expert consultation, training, and quality assurance at an affordable cost.
148,149

Onsite validation and field adoption
As highlighted in the 2016 O'Neill report on antimicrobial resistance, more effort should be put into the development of new diagnostics for bacterial detection, identification, and antimicrobial susceptibility testing. 150 Promising new technologies are increasingly being used in clinical bacteriology (table 1) , but when applied to low-resource settings there are budgetary, technical, human resource, and behavioural constraints and such technologies are rarely implemented outside of reference laboratories. 25 Furthermore, in low-resource settings, clinical performance studies are a major bottleneck to the development of diagnostics. 151 Specifically, many diagnostics are not tested in low-resource settings because of financial or operational constraints; therefore, their implementation in these settings is delayed.
Some manufacturers are forming partnerships and investing in research exploring low-cost diagnostic innovation 86 and some of those technologies might develop into valuable diagnostics for low-resource settings. Rather than awaiting accreditation in resourcerich settings, new diagnostics could be evaluated in field settings in low-resource setting. Some of these 
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innovations might then diffuse to high-resource settings, a process called reverse innovation. 152, 153 Well-functioning quality assured diagnostic labo ratories could constitute reliable study sites to carry out clinical diagnostic studies in the target population. Beyond strict diagnostic performance, such studies should address the adoption of new diagnostics into practice, their integration into clinical care, and cost-effectiveness. 154 
Beyond the six building blocks
Other factors can influence the implementation of clinical bacteriology in low-resource settings. Political commitment is essential to instal and equip clinical laboratories at all levels of health care and to strengthen health systems. It is therefore worth noting the recent resolution of the UN General Assembly, wherein Heads of State agreed to a broad, coordinated approach to tackle the root causes of antimicrobial resistance. 8 The announcement by WHO of a forthcoming Essential Diagnostics List could also help to integrate diagnostic resources better adapted to low-income settings into national programmes. 155 In addition, the professional, academic, and regulatory environment should facilitate implementation of clinical bacteriology in health-care organisation and bio medical curricula. Reference laboratories in low-resource settings should extend their capacity to support basic bacteriology and antimicrobial resistance, 156 rather than perpetuating existing silos through the restriction of their activities to HIV, tuberculosis, or malaria reference work. 41, 145 Further opportunities to support the implemen tation of clinical bacteriology are linkage to the WHO prequalification programme of in-vitro diagnostics 157 and extension of the Maputo Declaration goals to include clinical bacteriology. 23 Furthermore, in response to the 2016 O'Neill report on antimicrobial resistance, 150 wherein a Global Innovation Fund for non-commercial research was proposed, there have been calls for the development of a Global Antimicrobial Conservation Fund. 158 We strongly endorse this initiative, which-in collaboration with the UK Fleming Fund-would further support the provision of basic bacteriology services in low-resource settings.
159
Conclusions
Given the global attention given to antimicrobial resistance and several calls to action, 7, 160, 161 it is time to address the issue of strengthening clinical bacteriology in low-resource settings. The benefits of clinical bacteriology are numerous, not only for individual patient care, but also for surveillance of outbreaks and emerging resistance, and also management of hospital infections and antimicrobial usage. The reference laboratories and networks, which were established in response to WHO's Maputo declaration on laboratory strengthening for the Grades of relevance and feasibility are shown as ++++ (high), +++ (moderate), ++ (low), or + (very low). Preanalytical feasibility refers to indications, sampling, and transport; analytical feasibility refers to technical (eg, selective culture media or incubation conditions) and human (training or expertise) requirements. We have outlined some challenges that might be encountered during the implementation of clinical bacteriology in low-resource settings and provide a framework as to how these difficulties could be overcome. The substantial progress made in the diagnosis and management of HIV, tuberculosis, and malaria has shown that non-expert staff can effectively deliver services that were previously considered too complicated and demanding. 162 With similar concerted international efforts on an international scale, we believe such progress could be achieved for clinical bacteriology.
